Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener Medizinische Wochenschrift
Erschienen in:

01.06.2012 | main topic

TBE—update on vaccination recommendations for children, adolescents, and adults

verfasst von: Tomas Jelinek, MD, PhD, DTM&H

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 11-12/2012

Einloggen, um Zugang zu erhalten

Summary

Vaccines against tick-born encephalitis (TBE) are well established in Europe. Two highly immunogenic and safe products are available, FSME-IMMUN and Encepur. Extensive research has been published regarding all aspects of standard and rapid immunization schedules, covaccination, and vaccine interchangeability. Long-term effectiveness and resulting recommendations for booster intervals remain topics of discussion. Vaccination is recommended in Switzerland and in Germany for adults and children living in, or travelling to, endemic areas. Austria has recommended universal vaccination since 1981. It is noteworthy that Austria is the only country in Europe that has experienced a decrease in caseload during the last 20 years. This is almost certainly due to the very high vaccine coverage rate of 86 %.
Vorheriger Artikel Tick-borne encephalitis in children
Nächster Artikel Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?
Literatur
1.
WHO. Vaccines against tick-borne encephalitis: WHO position paper. Weekly Epidemiological Record. 2011;86:241–56.
2.
Holzmann H, Kundi M, Stiasny K, Clement J, McKenna P, Kunz C, et al. Correlation between ELISA, hemagglutination inhibition, and neutralization tests after vaccination against tick-borne encephalitis. J Med Virol. 1996;48:102–7.PubMedCrossRef
3.
Demicheli V, Debalini MG, Rivetti A. Vaccines for preventing tick-borne encephalitis. Cochrane Database Syst Rev. 2009:CD000977.
4.
Schoendorf I, Ternak G, Oroszlan G, Nicolay U, Banzhoff A, Zent O. Tick-born encephalitis (TBE) vaccination in children: advantage of the rapid immunization schedule (i.e., days 0, 7, 21). Hum Vaccin. 2007;3:42–7.PubMedCrossRef
5.
Paulke-Korinek M, Rendi-Wagner P, Kundi M, Laaber B, Wiedermann U, Kollaritsch H. Booster vaccinations against tick-borne encephalitis: 6 years follow-up indicates long-term protection. Vaccine. 2009;27:7027–30.PubMedCrossRef
6.
Hainz U, Jenewein B, Asch E, Pfeiffer KP, Berger P, Grubeck-Loebenstein B. Insufficient protection for healthy elderly adults by tetanus and TBE vaccines. Vaccine. 2005;23:3232–5.PubMedCrossRef
7.
Weinberger B, Keller M, Fischer KH, Stiasny K, Neuner C, Heinz FX, et al. Decreased antibody titers and booster responses in tick-borne encephalitis vaccinees aged 50–90 years. Vaccine. 2010;28:3511–5.PubMedCrossRef
8.
Stiasny K, Holzmann H, Heinz FX. Characteristics of antibody responses in tick-borne encephalitis vaccination breakthroughs. Vaccine. 2009;27:7021–6.PubMedCrossRef
9.
Andersson CR, Vene S, Insulander M, Lindquist L, Lundkvist A, Gunther G. Vaccine failures after active immunization against tick-borne encephalitis. Vaccine. 2010;28:2827–31.PubMedCrossRef
10.
Heinz FX, Holzmann H, Essl A, Kundi M. Field effectiveness of vaccination against tick-borne encephalitis. Vaccine. 2007;25:7559–67.PubMedCrossRef
11.
Rendi-Wagner P, Zent O, Jilg W, Plentz A, Beran J, Kollaritsch H. Persistence of antibodies after vaccination against tick-borne encephalitis. Int J Med Microbiol. 2006;296(Suppl 40):202–7.PubMedCrossRef
12.
Rendi-Wagner P, Paulke-Korinek M, Kundi M, Wiedermann U, Laaber B, Kollaritsch H. Antibody persistence following booster vaccination against tick-borne encephalitis: 3-year post-booster follow-up. Vaccine. 2007;25:5097–5101.PubMedCrossRef
13.
Plentz A, Jilg W, Schwarz TF, Kuhr HB, Zent O. Long-term persistence of tick-borne encephalitis antibodies in adults 5 years after booster vaccination with Encepur® Adults. Vaccine. 2009;27:853–6.PubMedCrossRef
14.
Wittermann C, Schondorf I, Gniel D. Antibody response following administration of two pediatric tick-borne encephalitis vaccines using two different vaccination schedules. Vaccine. 2009;27:1661–6.PubMedCrossRef
15.
Petri E, Gniel D, Zent O. Tick-borne encephalitis (TBE) trends in epidemiology and current and future management. Travel Med Infect Dis. 2010;8:233–45.PubMedCrossRef
16.
Anonymous. Risikogebiete in Deutschland. Epid Bull. 2011;17:133–45.
Metadaten
Titel
TBE—update on vaccination recommendations for children, adolescents, and adults
verfasst von
Tomas Jelinek, MD, PhD, DTM&H
Publikationsdatum
01.06.2012
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 11-12/2012
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-012-0112-1

Weitere Artikel der Ausgabe 11-12/2012

Tick-borne encephalitis in children

  • main topic

Tick-borne encephalitis: Clinical findings and prognosis in adults

  • main topic

Tick-borne Encephalitis—still a serious disease?

  • editorial

Eingeschränkter Zugang zur internationalen medizinischen Fachliteratur in der ehemaligen Sowjetunion

  • letter to the editor

Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?

  • review

Cognitive-enhancing substance use at German universities: frequency, reasons and gender differences

  • original article